## Roger J Laham

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1598427/publications.pdf

Version: 2024-02-01

70 papers

3,220 citations

257429 24 h-index 56 g-index

70 all docs

70 docs citations

70 times ranked

2800 citing authors

#	Article	IF	CITATIONS
1	Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2. Circulation, 2002, 105, 788-793.	1.6	621
2	Local Perivascular Delivery of Basic Fibroblast Growth Factor in Patients Undergoing Coronary Bypass Surgery. Circulation, 1999, 100, 1865-1871.	1.6	398
3	Clinical Trials in Coronary Angiogenesis: Issues, Problems, Consensus. Circulation, 2000, 102, E73-86.	1.6	390
4	Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a Phase I open-label dose escalation study. Journal of the American College of Cardiology, 2000, 36, 2132-2139.	2.8	216
5	Therapeutic Angiogenesis With Basic Fibroblast Growth Factor: Technique and Early Results. Annals of Thoracic Surgery, 1998, 65, 1540-1544.	1.3	213
6	Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. Journal of Thoracic and Cardiovascular Surgery, 2002, 124, 28-34.	0.8	145
7	Diagnosis of obstructive coronary artery disease using computed tomography angiography in patients with stable chest pain depending on clinical probability and in clinically important subgroups: meta-analysis of individual patient data. BMJ: British Medical Journal, 2019, 365, l1945.	2.3	99
8	Macrophage-Dependent Regulation of Syndecan Gene Expression. Circulation Research, 1997, 81, 785-796.	4.5	83
9	Evaluation of Changes in Functional Status in the Year After Aortic Valve Replacement. JAMA Internal Medicine, 2019, 179, 383.	5.1	68
10	Intrapericardial administration of basic fibroblast growth factor: Myocardial and tissue distribution and comparison with intracoronary and intravenous administration. Catheterization and Cardiovascular Interventions, 2003, 58, 375-381.	1.7	55
11	Longevity of the Placebo Effect in the Therapeutic Angiogenesis and Laser Myocardial Revascularization Trials in Patients With Coronary Heart Disease. American Journal of Cardiology, 2005, 95, 1456-1459.	1.6	55
12	Preventing Coronary Obstruction During Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2021, 14, 941-948.	2.9	55
13	Coronary Angiogenesis: Detection in Vivo with MR Imaging Sensitive to Collateral Neocirculation—Preliminary Study in Pigs. Radiology, 2000, 214, 801-807.	7.3	49
14	Gene Transfer for Angiogenesis in Coronary Artery Disease. Annual Review of Medicine, 2001, 52, 485-502.	12.2	48
15	Exercise-induced expression of VEGF and salvation of myocardium in the early stage of myocardial infarction. American Journal of Physiology - Heart and Circulatory Physiology, 2009, 296, H389-H395.	3.2	47
16	Pharmacokinetics and Pharmacodynamics of Recombinant FGFâ€2 in a Phase I Trial in Coronary Artery Disease. Journal of Clinical Pharmacology, 2001, 41, 378-385.	2.0	44
17	Spatial Heterogeneity in VEGF-induced Vasodilation: VEGF Dilates Microvessels but Not Epicardial and Systemic Arteries and Veins. Annals of Vascular Surgery, 2003, 17, 245-252.	0.9	41
18	Subxyphoid access of the normal pericardium: A novel drug delivery technique. Catheterization and Cardiovascular Interventions, 1999, 47, 109-111.	1.7	40

#	Article	IF	CITATIONS
19	Magnetic resonance imaging demonstrates improved regional systolic wall motion and thickening and myocardial perfusion of myocardial territories treated by laser myocardial revascularization. Journal of the American College of Cardiology, 2002, 39, 1-8.	2.8	35
20	TRANSENDOCARDIAL AND TRANSEPICARDIAL INTRAMYOCARDIAL FIBROBLAST GROWTH FACTOR-2 ADMINISTRATION: MYOCARDIAL AND TISSUE DISTRIBUTION. Drug Metabolism and Disposition, 2005, 33, 1101-1107.	3.3	35
21	Modulation of myocardial perfusion and vascular reactivity by pericardial basic fibroblast growth factor: Insight into ischemia-induced reduction in endothelium-dependent vasodilatation. Journal of Thoracic and Cardiovascular Surgery, 1998, 116, 1022-1028.	0.8	34
22	Effectiveness of rheolytic coronary thrombectomy with the AngioJet catheter. American Journal of Cardiology, 2002, 90, 470-476.	1.6	34
23	Therapeutic angiogenesis for myocardial ischemia. Expert Review of Cardiovascular Therapy, 2004, 2, 271-283.	1.5	33
24	Contemporary Discrepancies of Stenosis Assessment by Computed Tomography and Invasive Coronary Angiography. Circulation: Cardiovascular Imaging, 2019, 12, e007720.	2.6	28
25	<i>In vitro</i> and <i>in vivo</i> degradation of poly( <scp>D,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 507 Journal of Biomedical Materials Research - Part A, 2011, 96A, 632-638.</scp>	Td (L4.0	)>â€lactide 26
26	A Practical Twoâ€Stage Frailty Assessment for Older Adults Undergoing Aortic Valve Replacement. Journal of the American Geriatrics Society, 2019, 67, 2031-2037.	2.6	26
27	Bone marrow transplantation for the heart: fact or fiction?. Lancet, The, 2003, 361, 11-12.	13.7	24
28	Frailty Phenotype and Deficit Accumulation Frailty Index in Predicting Recovery After Transcatheter and Surgical Aortic Valve Replacement. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2019, 74, 1249-1256.	3.6	24
29	Delirium Incidence and Functional Outcomes After Transcatheter and Surgical Aortic Valve Replacement. Journal of the American Geriatrics Society, 2019, 67, 1393-1401.	2.6	24
30	Comparison of VEGF Delivery Techniques on Collateral-Dependent Microvascular Reactivity. Microvascular Research, 1998, 55, 175-178.	2.5	22
31	Gene transfer to induce angiogenesis in myocardial and limb ischaemia. Expert Opinion on Biological Therapy, 2001, 1, 985-994.	3.1	15
32	Relationship of left ventricular mass to coronary atherosclerosis and myocardial ischaemia: the CORE320 multicenter study. European Heart Journal Cardiovascular Imaging, 2015, 16, 166-176.	1.2	14
33	Angiogenesis: Bench to Bedside, Have We Learned Anything?. Toxicologic Pathology, 2006, 34, 3-10.	1.8	13
34	Extent of myocardial collateralization: Determination with three-dimensional elastic-subtraction spiral CT. Academic Radiology, 1997, 4, 680-686.	2.5	12
35	Therapeutic angiogenesis for coronary artery disease. Current Treatment Options in Cardiovascular Medicine, 2002, 4, 65-74.	0.9	11
36	Autologous Cardiomyotissue Implantation Promotes Myocardial Regeneration, Decreases Infarct Size, and Improves Left Ventricular Function. Circulation, 2011, 123, 62-69.	1.6	9

#	Article	IF	CITATIONS
37	Percutaneous retrieval of fractured bird's nest IVC filter penetrating into aorta. Catheterization and Cardiovascular Interventions, 2012, 80, 657-660.	1.7	9
38	Fatal Hemoptysis After Closure of Gastrobronchial Fistula Using an Amplatzer Vascular Device. Annals of Thoracic Surgery, 2018, 105, e71-e73.	1.3	9
39	Prognostic value of noninvasive combined anatomic/functional assessment by cardiac CT in patients with suspected coronary artery disease — Comparison with invasive coronary angiography and nuclear myocardial perfusion imaging for the five-year-follow up of the CORE320 multicenter study. lournal of Cardiovascular Computed Tomography, 2021, 15, 485-491.	1.3	9
40	Safety of subxyphoid pericardial access using a blunt-tip needle. American Journal of Cardiology, 2002, 89, 891-893.	1.6	8
41	Therapeutic angiogenesis: protein-based therapy for coronary artery disease. Expert Opinion on Pharmacotherapy, 2003, 4, 219-226.	1.8	8
42	Meta-Analysis Comparing Valve Durability Among Different Transcatheter and Surgical Aortic Valve Bioprosthesis. American Journal of Cardiology, 2021, 158, 104-111.	1.6	8
43	Intracardiac echocardiography and fluoroscopy guided percutaneous left ventricular pseudoaneurysm closure. Catheterization and Cardiovascular Interventions, 2013, 82, E915-8.	1.7	7
44	A 3-Dimensionally Printed, High-Fidelity Ultrasound-Guided Pericardiocentesis Training Model. Journal of Cardiothoracic and Vascular Anesthesia, 2020, 34, 245-247.	1.3	7
45	<p>Physical Performance and Risk of Postoperative Delirium in Older Adults Undergoing Aortic Valve Replacement</p> . Clinical Interventions in Aging, 2020, Volume 15, 1471-1479.	2.9	7
46	Therapeutic Angiogenesis. BioDrugs, 2000, 14, 13-20.	4.6	6
47	Intramyocardial delivery of FGF2 in combination with radio frequency transmyocardial revascularization. Catheterization and Cardiovascular Interventions, 2001, 53, 429-434.	1.7	6
48	Repeated successful balloon valvuloplasty of a bioprosthetic aortic valve in a nonagenerian. Catheterization and Cardiovascular Interventions, 2011, 77, 589-592.	1.7	6
49	Histopathological Demonstration of Subacute Endothelialization Following Aneurysm Retreatment with the Pipeline Embolization Device. World Neurosurgery, 2018, 118, 156-160.	1.3	6
50	Comparative utility of frailty to a general prognostic score in identifying patients at risk for poor outcomes after aortic valve replacement. BMC Geriatrics, 2020, 20, 38.	2.7	6
51	Longâ€term clinical safety and efficacy of drugâ€coated balloon in the treatment of inâ€stent restenosis: A metaâ€analysis and systematic review. Catheterization and Cardiovascular Interventions, 2020, 96, E129-E141.	1.7	5
52	Cognition, Frailty, and Functional Outcomes of Transcatheter Aortic Valve Replacement. American Journal of Medicine, 2020, 133, 1219-1222.	1.5	5
53	Heterotopic caval valve implantation for the management of severe tricuspid regurgitation: a case series. European Heart Journal - Case Reports, 2021, 5, ytaa428.	0.6	4
54	Combined percutaneous biosense-guided laser myocardial revascularization and coronary intervention. Catheterization and Cardiovascular Interventions, 2001, 53, 235-240.	1.7	3

#	Article	IF	CITATIONS
55	Anecdotal vs. evidenceâ€based, off label use of drug eluting stents for infrapopliteal disease: Abusus non tollit usum (Misuse does not nullify proper use). Catheterization and Cardiovascular Interventions, 2008, 71, 112-113.	1.7	3
56	Skin-derived microorgan autotransplantation as a novel approach for therapeutic angiogenesis. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 294, H213-H219.	3.2	3
57	Early outcomes from the <scp>CLASP IID</scp> trial rollâ€in cohort for prohibitive risk patients with degenerative mitral regurgitation. Catheterization and Cardiovascular Interventions, 2021, 98, E637-E646.	1.7	3
58	CoreValve bioprosthesis dysfunction treated with a Sapien 3 valveâ€inâ€valve transcatheter aortic valve replacement and BASILICA technique. Catheterization and Cardiovascular Interventions, 2021, 98, 403-406.	1.7	2
59	Novel use of preprocedure imaging for planning and guidance of right atrium–to–left ventricle access for catheter ablation of ventricular tachycardia. HeartRhythm Case Reports, 2021, 7, 726-730.	0.4	1
60	Lessons for Treating Structural Heart Patients During the COVID-19 Pandemic and Beyond. Structural Heart, 2021, 5, 591-595.	0.6	1
61	No-Option Patients., 2005,, 1-17.		1
62	Effects of B-type natriuretic peptide (nesiritide) on coronary epicardial arteries, systemic vasculature and microvessels. Journal of Invasive Cardiology, 2008, 20, 76-80.	0.4	1
63	Transmyocardial Laser Revascularization. , 2012, , 75-87.		0
64	Unusual Cause of Left Ventricular Outflow Tract Obstruction Following Transcatheter Mitral Valve-in-Ring Replacement. Case, 2021, 5, 147-153.	0.3	0
65	Transcatheter mitral valveâ€inâ€valveâ€inâ€valve replacement with transseptal puncture in the presence of an atrial septal occluder device. Echocardiography, 2021, 38, 1425-1429.	0.9	0
66	Enhanced IAPâ€⊋ expression is critical for the resistance of endothelial cells to TNFâ€Î±â€induced apoptosis. FASEB Journal, 2006, 20, LB72.	0.5	0
67	Percutaneous Treatment of Coronary Artery Disease. , 2010, , 263-286.		0
68	Mechanical discordance between left atrium and left atrial appendage. Annals of Cardiac Anaesthesia, 2018, 21, 82-84.	0.6	0
69	The Many Faces of the Interatrial Septum: A Diagnostic Dilemma and Considerations for Defect Closure Device Selection. Journal of Cardiothoracic and Vascular Anesthesia, 2022, , .	1.3	0
70	The treatment of peripheral vascular disease: scio me nihil scire. Journal of Invasive Cardiology, 2009, 21, 282.	0.4	0